Newly published details of interim clinical data for Takeda's candidate vaccine for dengue show activity across all serotypes that seems to bode well for an ongoing Phase III trial with the potential rival to the only currently available vaccine, Sanofi's Dengvaxia.

Japan's GHIT Fund is making new investments in a slew of pipeline projects for malaria, tuberculosis, leishmaniasis and dengue that involve local pharma industry and other academic partners.

Davinder Gill provides an update on the sharpened focus of the New Delhi-based MSD-Wellcome Trust Hilleman Laboratories as it seeks to narrow its research and development focus in developing vaccines for low-income emerging markets.

GSI has developed a system combining DNA chip production and analysis with proteomics tools to provide an integrated drug discovery solution to pharmaceutical and biotech customers.